trial
as of 2026-07-01Berberine Improving Cognitive Impairments in Schizophrenia
NCTId NCT07359209
at a glance
— · Completed
Enrollment 124 (actual)
Sponsored by Tianjin Anding Hospital
Primary completion 2026-01-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Completed
Enrollment
124 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2023-07-21
Primary completion
2026-01-30
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Tianjin Anding HospitalLead Sponsor
Sites
1 total
Tianjin, China
Facts & assertions
4 sourced
Enrollment
124
Phase
NA
Primary Completion Date
2026-01-30
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication